NWBO
NWBO clinical trials: NORTHWEST BIOTHERAPEUTICS INC
Every trial on ClinicalTrials.gov where NORTHWEST BIOTHERAPEUTICS INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 9
- Trials linked
- 5
- As lead sponsor
- 4
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
NWBO on the catalyst calendar · NWBO registry changes
- Primary completion Nov 2022Sponsor estimatePhase 3NCT00045968Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain CancerNorthwest Biotherapeutics · Glioblastoma MultiformeUnknown statusNWBOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2019Sponsor estimatePhase 1NCT03638765Dendritic Cell Therapy for Brain Metastases From Breast- or Lung CancerNorthwest Biotherapeutics · Brain MetastasesUnknown statusNWBOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT02146066Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221Northwest Biotherapeutics · GBMAvailableNWBOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2016Sponsor estimatePhase 1/Phase 2NCT01882946Safety and Efficacy Study of DCVax-Direct in Solid TumorsNorthwest Biotherapeutics · Locally Advanced TumorUnknown statusNWBOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredPhase 3NCT00043212Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.Northwest Biotherapeutics · Prostate CancerWithdrawnNWBOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2028Sponsor estimatePhase 2NCT07634094Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage...Kalinski, Pawel, MD, PhD · Ovarian CancerNot yet recruitingAIMCollaboratorNWBOCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2020Sponsor estimatePhase 2NCT03014804Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent GlioblastomaJonsson Comprehensive Cancer Center · Giant Cell GlioblastomaWithdrawnNWBOCollaboratorBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2013Sponsor estimatePhase 1/Phase 2NCT00603460DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal CancerUniversity of Pennsylvania · Ovarian CancerWithdrawnNWBOCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2009ActualPhase 1NCT00683241A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal CancerAbramson Cancer Center at Penn Medicine · Ovarian CancerCompletedNWBOCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner